In vivo interaction of endotoxin and recombinant bactericidal/permeability-increasing protein (rBPI23): Hemodynamic effects in a human endotoxemia model

Journal of Laboratory and Clinical Medicine

Volumn 140, Issue 4, 2002, Pages 228-235

  Jellema, Wilbert T ^a   Veerman, D Peter ^a   De Winter, Robbert J ^a   Wesseling, Karel H ^a   Van Deventer, Sander J H ^a   Hack, C Erik ^a   Van Lieshout, Johannes J ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0036793114     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2002.127170     Document Type: Article

References (55)

1. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-7.
2. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
3. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680-7.
4. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-3.
5. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429-36.
6. Vincent JL. Search for effective immunomodulating strategies against sepsis. Lancet 1998;351:922-3.
7. Weiss J, Elsbach P, Shu C, Castillo J, Grinna L, Horwitz A, et al. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992;90:1122-30.
8. Arditi M, Zhou J, Huang SH, Luckett PM, Marra MN, Kim KS. Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury. Infect Immun 1994;62:3930-6.
9. Hubacek JA, Buchler C, Aslanidis C, Schmitz G. The genomic organization of the genes for human lipopolysaccharide binding protein (LBP) and bactericidal permeability increasing protein (BPI) is highly conserved. Biochem Biophys Res Commun 1997;236:427-30.
10. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW. Bactericidal/permeability increasing protein has endotoxin-neutralizing activity. J Immunol 1990;144:662-6.
11. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992;148:532-7.
12. Fransen E, Maessen J, Dentener M, Senden N, Geskes G, Buurman W. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998;113:1290-5.
13. Sundaram S, King AJ, Pereira BJ. Lipopolysaccharide-binding protein and bactericidal/permeability-increasing factor during hemodialysis: clinical determinants and role of different membranes. J Am Soc Nephrol 1997;8:463-70.
14. Haapamaki MM, Haggblom JO, Gronroos JM, Pekkala E, Alanen K, Nevalainen TJ. Bactericidal/permeability-increasing protein in colonic mucosa in ulcerative colitis. Hepatogastroenterology 1999;46:2273-7.
15. Gazzano-Santoro H, Parent JB, Grinna L, Horwitz A, Parsons T, Theofan G, et al. High-affinity binding of the bactericidal/permeability increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipolopolysaccharide. Infect Immun 1992;60:4754-61.
16. Nishimura H, Gogami A, Miyagawa Y, Nanbo A, Murakami Y, Baba T, et al. Bactericidal/permeability-increasing protein promotes complement activation for neutrophil-mediated phagocytosis on bacterial surface. Immunology 2001;103:519-25.
17. Marra MN, Thornton MB, Snable JL. Wilde CG, Scott RW. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 1994;22:559-65.
18. Opal SM, Fisher CJ, Marra MN, Scott RW, Palardy JE, Brown U. Bactericidal/Permeability-increasing protein as a novel therapeutic modality in the treatment of endotoxic shock. Clin Res 1991;39:351A.
19. Fisher CJ, Marra MN, Palardy JE, Marchbanks CR, Scott RW, Opal SM. Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: A placebo-controlled study. Crit Care Med 1994;22:553-8.
20. Kimmings AN, van Deventer SJ, Obertop H, Gouma DJ. Treatment with recombinant bactericidal/permeability-increasing protein to prevent endotoxin-induced mortality in bile duct-ligated rats. J Am Coll Surg 1999;189:374-9.
21. Wiezer MJ, Meijer C, Sietses C, Prins HA, Cuesta MA, Beelen RH, et al. Bactericidal/permeability-increasing protein preserves leukocyte functions after major liver resection. Ann Surg 2000;232:208-15.
22. de Winter RJ, von der Mohlen MA, Van Lieshout JJ, Wedel N, Nelson B, Friedmann N, et al. Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans. J Inflamm 1995;45:193-206.
23. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt-Bersma RJ, et al. Quantification of plasma factor XIIa-C1(-)-inhibitor and kallikrein-C1(-)-inhibitor complexes in sepsis. Blood 1988;72:1841-8.
24. Citarella F, Wuillemin WA, Lubbers YT. Hack CE. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 1997;99:197-205.
25. Friedman DB, Jensen FB, Matzen S, Secher NH. Non-invasive blood pressure monitoring during head-up tilt using the Penaz principle. Acta Anaesthesiol Scand 1990;34:519-22.
26. Jellema WT, Imholz BPM, Van Goudoever J, Wesseling KH, Van Lieshout JJ. Finger arterial versus intrabrachial pressure and continuous cardiac output during head-up tilt testing in healthy subjects. Clin Sci 1996;91:193-200.
27. Wesseling KH, Settels JJ, Van der Hoeven GMA, Nijboer JA, Butijn MWT, Dorlas JC. Effects of peripheral vasoconstriction on the measurement of bloodpressure in a finger. Cardiovasc Res 1985;19:139-45.
28. Harms MPM, Wesseling KH, Pott F, Jenstrup M, van Goudoever J, Secher NH, et al. Continuous stroke volume monitoring by modelling flow from non-invasive measurement of arterial pressure in humans under orthostatic stress. Clin Sci 1999;97:291-301.
29. Hirschl MM, Binder M, Gwechenberger M, Hirkner H, Bur A, Kittler H, et al. Noninvasive assessment of cardiac output in critically ill patients by analysis of the finger blood pressure waveform. Crit Care Med 1997;25:1909-14.
30. Wesseling KH, Jansen JRC, Settels JJ, Schreuder JJ. Computation of aortic flow from pressure in humans using a nonlinear, three-element model. J Appl Physiol 1993;74:2566-73.
31. Toorop GP, Westerhof N, Elzinga G. Beat-to-beat estimation of peripheral resistance and arterial compliance during pressure transients. Am J Physiol 1987;252:H1275-83.
32. Westerhof N, Elzinga G, Sipkema P. An artificial arterial system for pumping hearts. J Appl Physiol 1971;31:776-81.
33. Langewouters GJ, Wesseling KH, Goedhard WJA. The static elastic properties of 45 human thoracic and 20 abdominal aortas in vitro and the parameters of a new model. J Biomech 1984;17:425-535.
34. Von der Mohlen MAM, Kimmings AN, Wedel N, Mevissen ML, Jansen J, Friedman N, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans using a recombinant endotoxin-binding protein (rBPI23). J Clin Exp Pharmacol Physiol 1994;4:1-10.
35. Bevington PR. Data reduction and error analysis for the physical sciences. New York, NY: McGraw-Hill, 1969.
36. Hoque AM, Marczin N, Catravas JD, Fuchs LC. Anesthesia with sodium pentobarbital enhances lipopolysaccharide-induced cardiovascular dysfunction in rats. Shock 1996;6:365-70.
37. Fatehi-Hassanabad Z, Muller B, Andriantsitohaina R, Furman BL, Parratt JR, Stoclet JC. Influence of indomethacin on the haemodynamic effects of lipopolysaccharide in rats. Fundam Clin Pharmacol 1996;10:258-63.
38. Ammons WS, Kung AH. Recombinant amino terminal fragment of bactericidal/permeability-increasing protein prevents hemodynamic responses to endotoxin. Circ Shock 1993;41:176-84.
39. Lin Y, Ammons WS, Leach WJ, Kung AH. Protective effects of a recombinant N-terminal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. Shock 1994;2:324-31.
40. Koyama S, Shibamoto T, Ammons WS, Saeki Y. rBPI23 attenuates endotoxin-induced cardiovascular depression in awake rabbits. Shock 1995;4:74-8.
41. Giroir BP, Quint PA, Barton P, Kirsch EA, Kitchen L, Goldstein B, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997;350:1439-43.
42. Wenzel RP. Anti-endotoxin monoclonal antibodies-a second look. N Engl J Med 1992;326:1151-3.
43. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997;66:101-95.
44. Jellema WT, Wesseling KH, Groeneveld AB, Stoutenbeek CP, Thijs LG, Van Lieshout JJ. Continuous cardiac output in septic shock by simulating a model of the aortic input impedance: a comparison with bolus injection rhermodilution. Anesthesiology 1999;90:1317-28.
45. Law WR, Moriarty MT, McLane MP. Cardiovascular sequelae of endotoxin shock in diabetic dogs. Diabetologia 1991;34:687-94.
46. Weitzberg E, Hemsen A, Rudehill A, Modin A, Wanecek M, Lundberg JM. Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol 1996;118:617-26.
47. Darien BJ. Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acure lung injury model. Shock 1998;9:274-81.
48. Parkes DG, Coghlan JP, Scoggins BA. Pyrogenic stimulation of vascular resistance in conscious sheep. Life Sci 1995;57:599-608.
49. Forfia PR, Zhang X, Ochoa F, Ochoa M, Xu X, Bernstein R, et al. Relationship between plasma NOx and cardiac and vascular dysfunction after LPS injection in anesthetized dogs. Am J Physiol 1998;274:H193-201.
50. Palacios B, Pang CC. Protective effects of ethynylestradiol on the hemodynamic changes induced by lipopolysaccharide in anesthetized rats. J Cardiovasc Pharmacol 1998;31:479-83.
51. Beamer L J, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997;276:1861-4.
52. Jacob HS, Craddock PR, Hammerschmidt DE, Moldow CF. Complement-induced granulocyte aggregation: an unsuspected mechanism of disease. N Engl J Med 1980;302:789-94.
53. Raasveld MH, Surachno S, Hack CE, ten Berge RJ. Thromboembolic complications and dose of monoclonal OKT3 antibody. Lancet 1992;339:1363-4.
54. Raasveld MH, Hack CE, ten Berge RJ. Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association with distinct mediators. Thromb Haemost 1992;68:264-7.
55. von der Mohlen MA, Kimmings AN, Wedel NI, Mevissen ML, Jansen J, Friedmann N, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis 1995;172:144-51.